'''活性代謝產物'''('''active metabolite''')是[[藥物|藥物]]經[[代謝|代謝]]後產出，具有生理活性的分子。

== 藥物的代謝產物 ==
藥物分子經身體代謝，被修改後仍繼續對身體造成影響者，即為活性代謝產物。 通常這些影響與原分子相似且較弱，但仍可有可觀影響(如{{tsl|en|11-hydroxy-THC||11-hydroxy-THC}}, {{tsl|en|morphine-6-glucuronide||morphine-6-glucuronide}})。  有些藥如[[可待因|可待因]]以及[[曲马多|曲马多]]有比母藥強的代謝產物(各自為[[嗎啡|嗎啡]] 以及{{tsl|en|O-Desmethyltramadol||''O''-desmethyltramadol}} )<ref name="pmid10850391">{{cite journal |author=Haffen E, Paintaud G, Berard M, Masuyer C, Bechtel Y, Bechtel PR |title=On the assessment of drug metabolism by assays of codeine and its main metabolites |journal=Therapeutic Drug Monitoring |volume=22 |issue=3 |pages=258–65 |date=June 2000 |pmid=10850391 |doi= 10.1097/00007691-200006000-00005|url=}}</ref><ref name="pmid8764759">{{cite journal |author=Raffa RB |title=A novel approach to the pharmacology of analgesics |journal=The American Journal of Medicine |volume=101 |issue=1A |pages=40S–46S |date=July 1996 |pmid=8764759 |doi= 10.1016/s0002-9343(96)00137-4 }}</ref><ref name="pmid19515014">{{cite journal |author=Zhou SF, Zhou ZW, Yang LP, Cai JP |title=Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development |journal=Current Medicinal Chemistry |volume=16 |issue=27 |pages=3480–675 |year=2009 |pmid=19515014 |doi= 10.2174/092986709789057635|url=}}</ref>， 在這些案例代謝產物可能為療效貢獻了一大部分。  有時代謝產物具有毒性，必須小心監控以避免在體內累積。如[[哌替啶|哌替啶]]和{{tsl|en|Dextropropoxyphene||dextropropoxyphene}}.<ref name="pmid19515014"/><ref name="pmid18958460">{{cite journal |author=Coller JK, Christrup LL, Somogyi AA |title=Role of active metabolites in the use of opioids |journal=European Journal of Clinical Pharmacology |volume=65 |issue=2 |pages=121–39 |date=February 2009 |pmid=18958460 |doi=10.1007/s00228-008-0570-y |url=}}</ref>

== 前驅藥物 ==
{{main|前驅藥物}}
有些藥物一開始的狀態沒有活性，被設計成在體內代謝後產生活性成分。這類藥物叫做[[前驅藥物|前驅藥物]]。藥物被如此設計可能是因為:藥物在製造及儲存階段更穩定。或是更能被身體吸收，擁有較好的[[药物代谢动力学|药物代谢动力学]]特性。(如 [[lisdexamphetamine|lisdexamphetamine]]).<ref name="pmid19937841">{{cite journal |author=Müller CE |title=Prodrug approaches for enhancing the bioavailability of drugs with low solubility |journal=Chemistry & Biodiversity |volume=6 |issue=11 |pages=2071–83 |date=November 2009 |pmid=19937841 |doi=10.1002/cbdv.200900114 |url=}}</ref>

== 參考資料 ==
{{Reflist}}

==延伸閱讀==
* {{cite book|authors=Nedderman, Angus N.R. & Walker, Don K.|chapter=Metabolite testing in drug development|editor=Bonate, Peter L.|title=Pharmacokinetics in Drug Development: Advances and Applications, Volume 3|publisher=Springer|year=2011|isbn=9781441979360|url=http://books.google.com/books?id=MUYUeKb_rpIC&pg=PA131|access-date=2016-03-04|archive-date=2014-07-29|archive-url=https://web.archive.org/web/20140729155422/http://books.google.com/books?id=MUYUeKb_rpIC&pg=PA131|dead-url=no}}

==參見==
*[[代謝產物|代謝產物]]
*[[前體|前體]]

[[Category:代谢|Category:代谢]]
[[Category:药代动力学|Category:药代动力学]]